Существенного нарастания частоты онкопатологии на фоне лечения МТ не отмечено (A. Nyfos и соавт., 1983).

10-ДИАЗАМИНОПТЕРИН (10-DEAZAAMINOPTERIN)

10-ДАМ — новый аналог фолатов, используемый для лечения РА. По данным G. Alarcon и соавт. (1992), эффективность и токсичность 10-ДАМ сходны с МТ.

Список литературы К главе "Метотрексат"

1.Alarcon G. S., Tracy I. C., Blackburn W. D.: Methotraxate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum., 1989; 32: 671-676.

2.Alarcon G. S., Schrohenloher R. E., Bartolucci A. A. et al: Supression of rheumatoid factor production by metotrexate in patients with rheumatoid arthritis: Evidence for different influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum., 1990; 33: 1156.

3.Alarcon G. S., Castaneda 0., Ferrandiz M., et al.: Efficacy and safety of 10-deazaaminopterin in the treatment of rheumatoid arthritis. Arthritis Rheum., 1992; 35: 1318-1321.

4.Alarcon G. S., Lopez-Mendez A., Walter J., et al.: Radiographic evidence of disease progression im methotrexate treated and non methotrexate disease modifying antirheumatic drugs tested rheumatoid arthritis patients: a meta-analysis. J. Rheumatol, 1992; 19: 1868-1873.

5.Al-Awadhil, Dale P., McKendry R J. R.: Pancytopenia associated with low dose methotrexate therapy. A regional survey. J. Rheumatol. 1993; 20: 1121-1125.

6.Allen L. S., Groff G.: Treatment of Felty's syndrome with low dose oral methotrexate. Arthritis Rheum. 1986; 29: 902-905.

7.Altz-Smith M., Kendal L. G., Jr. Stamm A. M.: Cryptococcus associated with low-dose methotrexate for arthritis. Am. J. Med. 1987; 83: 179-181.

8.Andersen P. A., West S. G., O'Dell J. R., et al. Weekly pulse methotrexate in rheumatoid arthritis. Ann. Inter. Med., 1985; 103: 489-496.

9.Antonelli M. S., Moreland L. W., Brick J. E.: Herpes zoster in patients with RA treated with weekly, low dose methotrexate. Am. J. Med. 1991; 90: 295-298.

10.Baggott J. E., Morgan S. L., Ha T. S., et al: Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J. 1992; 282: 197-203.

11.Baggott J. E., Morgan S. L., Ha T.-S., et al. Antifolates in rheumatoid arthritis: a hypotetical mechanism of action. Clin. Exp. Rheumatol. 1993; II (Suppl. 8): S101-S105.

12.Barrera P., Boerbooms A. M., Janssen E. M, met al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arhtritis Rheum., 193; 36: 1070-1079.

13.Ваггега P., Van der Hoogen F. H. J., Boerbooms A. M. Th., et al. Metotrexate-placebo controlled trial in systemic sclerosis: effects in circulating concentrations of bioactive interleukin-6. Brit. J. Rheumatol., 1994 (Sulll. 1); 33: 114 (abst.).

14.Barrera P., Laan F. J. M., Van Riel P. L. C. M., et al.: Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann. Rheum. Dis. 1994; 53: 434-439.

15.Barrera P., Boerbooms A. M. Th., Demacker P. N. M., et al.: Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose methotrexate, Br. J. Rheumatol 1994; 33: 1017-1024.

16.Bauer H., Breitbart A., Brado B., Pezzutto A.: Intravenous intensification of MTX-therapy in severe rheumatoid arthritis. Arthritis Rheum. 1993; 36 (suppl.): S232.

17.Bologna C., Edno L., Anava J, M., et al.: Methotrexate (MXT) concentration in synovial membrane (SM) of rheumatoid arthritis (RA) patients. Arthritis Rheum. 1993; 36 (suppl.): S80.

18.Bjorkman D. J., Boschert M., Tolman K., Clegg D., Ward J. R.: The effect of long-term metotrexate therapy on hepatic fibrosis in rheumatoid arthritis. Arthritis Rheum., 1993; 36: 1697.1701.

19.Bridges S. L, Jr. Lopez-Mendez A., Han K.-H., et al.: Should methotrexate be discontinued before elective orthopedic surgery in patients with RA. J. Rheumatol., 1991; 19: 984-988.

20.Buchbinder R., Hall S., Sambrook P. N., et al.: A life table review of 587 patients treated in community practice. J. Rheumatol. 1993; 20: 639-644.

21.Chang D. M., Weinblatt M. E., Schur P. H.: The effects of methotrexate on interleukin-I in patients with rheumatoid arthritis. J. Rheumatol. 1992: 19: 1678-1682.

22.Clegg D. O., Furst D. E., T9: Tolman K. G. et al.: Acute rever siblehepatic failure associated with methotraxate treatment of RA. J. Rheumatol. 1989; 16: 1123-1126.

23.Clegg D. O., and HCQ/MTX study group.; Combination hydroxychloroquine and methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1993; 36 (suppl.): S-53.

24.Connolly K. M, Stecher V. J., Danis E., et al.: Alteration of interleukin-I production and the acute phase response following medication of adjuvant arthritic rats with cyclosporin-A or methotrexate. Int. J. Pharmacol., 1988; 10: 717-728.

25.Cohen S., Rutstein J., Luggen M., et al. Comparison of the safety and efficacy of cyclosporin and methotrexat in refractory rheumatoid arthritis: a randomized, multicentered, placebo-controlled trial. Arthritis Rheum. 1993: 36 (suppl.): S-56.

26.Cronstein B. N., Eberle M. A., Gruber H. E., et al.: Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc. Natl. Acad. Sci. USA 1992; 88: 2441-2445.

27.Davidson J. R., Grazino P. M., Rothenburg R. J.: Methotrexate therapy for severe systemic lupus erythematosus. Arthritis Rheum. 1987; 30: 1195-1196.

28.Durk H., Koffler 1., Saal J. D.: Intraarticular methotrexate (MTX) therapy in corticosteroid resistant monoarthritis. Artritis Rheum. 1994; 37 (suppl.) S-252.

29.Fauci A. S. Treatment of glucocorticoid-resistent or relapsing Takayasu's arteritis with metotrexate. Arthritis Rheum. 1994; 37: 578-582.

30.Fietcher J. J., Miller D. R., Starkebaum G.: Reversal of neutropenia with methotrexate treatment in patients with Felty's syndrome: correletion of response with neutrophil-reac-tive IgG. Arthritis Rheum. 1989; 32: 194-201.

31.Firestein G. S., Paine M. M., Boyle D. L. Mechanism of metotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression. Arthritis Rhe um., 1994; 37: 193-200.

32.Fries J. F., Singh G., Lenert L., Furst D. E.: Aspirin, hydroxychloroquin, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum., 1990; 33: 1611-1619.

33.Fujii Т., Akizuki M., Matsumara M., et al.: Efficacy of methotrexate therapy in patients with adult Still's disease. Arthritis. Rheum. 1994; 37 (suppl.): S-417.

34.Furst D. E., Erickson N., Cluete L., et al.: Adverse experience with methotrexate during 176 weeks of a long-term prospective trial in RA. J. Rheumatol. 1990: 17: 1628-1635.

35.Furst D. E., Koehnke R., Burmeister L. F., et al.: Increasing methotrexate effect with increasing dose in the treatment or resistant rheumatoid arthritis. J. Rheumatol. 1989; 16: 313-320.

36.Furst D. E.: Should methotrexate be used to treat early rheumatoid arthritis. Semin. Arthritis Rheum. 1993; 6 (suppl. 2): 39-43.

37.Gabriel S., Regan E., O'Fallon M., et al.: Treatment of rheumatoid arthritis with higher dose intravenous methotrexate. J. Rheumatol. 1990; 17: 460-465.

38.Galarza D., Esquivel J., Villarreal M., et al.: Methotrexate in lupus nephritis: an uncontrolled study, preliminary results. Arthritis Rheum. 1992; 34 (suppl.): S187.

39.Gilbert S. C., Klintman G., Menter A., et al.: Methotrexate induced cirrhosis requiring liver transplantation in three patients with psoriasis. Arch. Int. Med. 1990; 150: 889-891.

40.Goddard D., Gutilla R., Clark M., Bomalaski J. L: Methotrexate inhibits eicosanoid biosynthesis in the rat air pouch through diminished phospholipase A2 activity. Arthritis Rheum. 1994; 137 (suppl,): S-253.

41.Grospham J., Weinblatt M. E.: Methotrexate: mechanism of action, pharmacokinetics, clinical indications, and toxicity. Curr. Opin. Rheumatol., 1991; 3: 363-368.

42.Gruberg L., Thaler M., Rozenman J. et al.: Nocardia asteroides infection complicating rheumatoid arthritis. J. Rheumatol, 1991; 18: 459-461.

43.Haagsma С., van Reid P., de Rooil D. J., van der Putte L.; Combination therapy In RA: sulphasalazine and methotrexate. Arthritis Rheum. 1993; 36 (suppl.): S-53.

44.Halla J. T., Hardin J. G.: Post-dosing reactions to methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1993; 36 (suppl.): S-80.

45.Handrock K., Reinhold-Keller E., Duncker G., et al.: Beneficial effects of low-dose methotrexate in Wegener's granulomatosis. Arhtritis Rheum. 1994: 37 (suppl.): S-353.

46.Haraoui B., Pelletier J. P., Cloutier J. M., et al.: Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs. Arthritis Rheum., 1991: 34: 153-163.

47.Harel L., Wagner-Weiner L., Poznanski A. K., et al. Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum., 1993; 10: 1370-1374.

48.Herman R. A., Veng-Pedersren P., Hoffman J., et. al. Pharmako kinetics of low-dose metotrexate in rheumatoid arthritis patients. J. Pharm. Sci., 1989; 78: 165-171.

49.Hernandes-Garcia С., Soraino С., Morando C., et al.: Methotrexate treatment in the management of giant cell arteritis. Scand. J. Rhgeumatol. 1994; 23: 295-298.

50.Hine R. J., Everson M. P., Hardin J. M., et al.: Methotrexate therapy in rheumatoid arthritis diminished lectin-induced mononuclear cell prolipheration. Rheumatol. Int., 1990; 10: 165-169.

51.Hirata S., Matsubara Т., Saura R., et al.: Inhibition of in vitro vascular endothelial cell prolipheration and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum., 1989; 32: 1065-1073.

52.Hoffman G. S., Leavitt R. Y., Kerr G. S., Fauci A. S.: The treatment of Wegeners's granulomatosis with glucocorticoids and metotrexate. Arthritis Rheum, ml992; 35: 1322-1329.

53.Hoffman G., Leavitt R., Kerr G., Rotterm M., Sneller M. C., Johnston C., Russel A. S., Aaron S.: The effect of in vivo and in vitro methotrexate on lymphocyte prolipheration as measured by uptake of tritiayed thymidine and tritiated guanosine. Clin. Exp. Rheumatol., 1988; 6: 391-393.

54.Jolivet J., Schilsky R. L., Bailey B. D., et al.: Synthesis, retention and biological activity of methotrexate polyglutamates in cultured human brest cancer cells. J. Clin. Invest., 1982; 70: 351360.

55.Joyce D. A., Wikk R. K., Hoffman D. M, et al.: Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann. Rheum. Dis.: 1991; 50: 913-914.

56.Kaye 0., Kahn M. F., Palazzo E., Bourgeois P.: Low dose methotrexate in musculoskeletal manifestations of sarcoidosis. Arthritis Rheum. 1993; 36 (suppl.): S-203.

57.Kerstens P. J. S. M., Boerbooms A. M. T. H., Jeurissen M. E. C., et al.: Accelerated nodulosis during low dose metotrexate therapy for rheumatoid arthritis. An analysis of ten cases. J. Rheumatol., 1992; 19: 867-871.

58.Kozlovski G., De Vito J. M., Kisicki J. C., Johnson J. B.: The effect of food on the absorbtion of metotrexate sodium tablets in healthy volunteres. Arthritis Rheum., 1992; 35: 761-764.

59.Kremer J. M., Phelps C. T. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rhe um., 1992; 35: 138-145.

60.Kremer J. M., Petrillo G. F., Lawrence D. A.: Methotrexate (MTX) induces significant changes in IL-1, IL-2. IL-6 and IL-8, but not lymphocyte markers in patients with rheumatoid arthritis. Arthritis Rheum. 1993: 36: S-77.

61.Kremer J. M.: The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J. Rheumatol. 1994; 21: 1-5.

62.Laurindo I. M. M., Mello S. B. V., de Falco V., et al.: Action of methotrexate on superoxide production (abstract). Rev. Esp. Rheumatol. 1993; 20 (suppl. 1): 6 ( 12).

63.Leff R. L, Case J. P., McKenzie R.: Rheumatoid arthritis, methotrexate therapy and pneumocystic pneumonoa. Ann. Int. Med. 1990; 1123: 716.

64.LeRoux J. L. Damon M., Chavis C., et al.: Effects of a single dose of metotrexate on 5-and 12lipoxygenase products in patients with rheumatoid arthritis. J Rheumatol., 1992; 19: 863-866.

65.Martinez-Osuna P., Zwolinska J. B., Sikes D. H., et al.: Lack of immunosupressive effect of lowdose oral methotrexate on lymphocytes in rheumatoid arthritis. Clin. Exp. Rheuma tol. 1993; II: 249254.

66.Marul Т., Matsubara Т., Mizuno К., Itoh H.: Inhibition of metalloproteinase activity derived from chondrocytes by MT. Arthritis Rheum. 1993; 36 (suppl.): S-79

67.Merrill J., Lahita R. G., Shen C., Cronstein B.: Rheumatoid nodulosis in patients treated with methotrexate: adenosin, acting primary at A2 receptors promote CR3-mediated formation of multinucleated giant cells (MGC) Arthritis Rheum. 1993: 36 (suppl): S-79.

68.Meyer F. A., Yaron I., Mashiah V., Yaron M.: Methotrexate inhibits proliferation but not interleukin I stimulated secretory activities of cultured human synovial fibroblasts. J. Rheumatol. 1993; 20: 238242.

69.Miescher P. A., Riethmuller D.: Diagnosis and treatment of systemic lupus erythematosus. Semin. Hematol. 1965; 2: 1-28.

70.Miller L. C., Cohen E. E., Orencole S. F. et al.: lnterleukin-1 beta is structurally related to dihydrofolate reductase: effects of methotrexate (abstract). Cytokine Res. 1988; 7: 49.

71.Montecucco C., Rossi S., Porta C.: Allopurinol mouthwasher in methotrexate-induced stomatitis. Arthritis Rheum. 1994; 37: 777-778.

72.Morand E. F., Axtens R. S. K., Littejohn G. O.: Combination methotrexate and sulphasala-sine therapy in patients with rheumatoid arthritis. Arthritis Rheum. 1993; 36 (suppl.): S-53.

73.Morgan S. L, Baggot J. T., Vaughn W. H., et al.: 5mg or 50 mg/week of folic acid supplementation does not alter the efficacy of methotrexate treated rheumatoid arthritis patients. Arthritis Rheum. 1992; 35 (suppl. 9): S343.

74.Morgan S. L., Alarcon G. S., Krumdieck C. L.: Folic acid supplementatrion during methotrexate therapy: It makes sense. J. Rheumatol. 1993; 20: 1121-1125.

75.Morgan S. L., Baggott J. E., Alarcon G. S.: Methotrexate and sulfasalazine combination therapy: is it worth the risk. Arthritis Rheum. 1993; 36: 281-282.

76.Morgan S. L. et al.: Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind placebo controlled trial. Ann. Int. Med., 1994; 121: 833-841. Nissar M., Carlisle L., Amas R. S.: Methotrexate and sulphasalazine combination therapy in rheumatoid arthritis. Br. J. Rheumatol. 1994; 7: 651-654.

77.Nyfors A., Jensen H.: Frequency of malignant neoplasms in 248 long term methotrexate treated psoriasis. Dermatologica 1983; 167: 260-261.

78.O'Callaghan J. W., Forrest M., Brooks P. M.: Inhibition of neutrophil chemotaxis in rheumatoid arthritis patients. Rheumatol. Int. 1988; 8: 41-45.

79.Oguey D., Kolliker F., Gerber N. J., Reichen J.: Effect of food on the bioavalability of low-dose metotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1992; 35: 611-614.

80.Olsen N. J., Callahan L. F., Pincus T. Immunologic studies of rheumatoid arthritis patients treated with metotrexate. Arthritis Rheum., 1987; 30: 481-488.

81.Olsen N. J., Murray L. M.: Antiprolipherative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum. 1989; 32: 378-385.

82.Paters L. J., Olsen N. J.: Mechanisms of action of metotrexate. Bull. Rheum. Dis., 1991; 41: 5-7.

83.Perhala R. S., Wlike W. S., Clough J. D., et al.: Local infectious complications following large replacement in RA patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum. 1991; 34: 146-152.

84.Philips C. A., Cera P. J., Mangan T. F., et al.: Clinical liver disease in patients with RA taking methotrexate. J. Rheumatol. 1992; 19: 229-233.

85.Plotz P. H., Dalakas M., Leff R. L., Love L. A., Miller F. W., Cronin M. E.: Current concepts in the idiopathic inflammatory myopathies: dermatomyositis and related disorders. Ann. Intern. Med. 1989; III: 143157.

86.Preston S. J., Diamond Т., Scott A., Laurent M. R.: Methotrexate osteopathy in rheumatic disease. Ann. Rheum. Dis. 1994; II: 13-16.

87.Rau R.: Metotrexate therapy in rheumatoid arthritis. Rheumatol. in Europe 1994; 23: 60-65.

88.Richardson В.: Methotrexare therapy for hearing loss in Cogan's syndrome. Arthritis Rheum. 1994; 37: 1559-1561.

89.Rothenburg R. J., Graziano F. M., Grandone J. T., et al,: The use of methotrexate in steroid resistant systemic lupus erythematosus. Arthritis Rheum. 1988; 31: 612-615.

90.Salaffi F., Carotti M., Cervini C.: A prospective study of the long-term efficacy and toxic-ity of lowdose methotrexate in rheumatoid arthritis. Clin. Exp. Rheumatol. 1995; 13: 23-28.

91.Sany J., Anaya J. M., Lussiez V., et al.: Treatment of rheumatoid arthritis with methotrexate: a prospective open-term study of 191 case. J. Rheumatol. 1991; 18: 1323-1327.

92.Schnabel A., Gross W. L.: Low-dose methotrexate in rheumatic disease-efficacy, side effects, risk factors for side effects. Semin. Arthritis Rheum., 1994; 23: 310-327.

93.Schnabel A., Reinhold-Keller E., Willmann V., Gross W. L.: Tolerabillity of metotrexate starting with 15 to 25 mg/week for rheumatoid arthritis. Rheum. Int. 1994; 14: 33-38.

94.Seibord J. R., McCloskey D. A., Furst D. E.: Pilot trial of methotrexate (MTX) in treatment of early diffuse scleroderma. Arthritis Rheum. 1994; 37 (suppl.): S-262.

95.Seideman P., Albertioni R., Beck O., et. al. Chloroquine reduced the bioavailability of metotrexate in patients with rheumatoid arthritis. Arthritis Rheum., 1994, 37: 830-833.

96.Segal R., Caspi D., Tisher M., et al.: Short term effects of low dose methotrexate on the acute phase reaction in rheumatoid arthritis. J. Rheumatol. 1989; 16: 14-18.

97.Segal R., Mozes E., Yaron M., Tartakowsky B.: The effects of methotrexate on the production and activity of interleukin 1. Arthritis Rheum. 1990; 32: 370-377.

98.Segal R., Yaron M., Tartakovsky B.: Methotrexate: mechanism of action in rheumatoid arthritis. Semin. Arthritis Rheum., 1990; 20: 190-200.

99.Segal R., Yaron M., Tartakowsky B.: Rescue of interleukin-I activity by leukovorin following inhibition by methotrexate in a murine in vitro system. Arthritis Rheum. 1990; 33: 1745-1749.

100.Shatten S., Asherson R. A., Hughes G. R. V.: Methotrexate (MTX) therapy for systemic lupus erythematosus (SLE) and SLE overlap syndrome. Arthritis Rheum. 1992; 34 (suppl.): S187.

101.Shergy W. J., Polisson P. P., Cadwell D. S. et al.: Methotrexate associated hepatotoxicity: Retrospective analysis of 210 patients with RA. Am. J. Med. 1988; 85: 771-777.

102.Shiroky J. B., Frost A., Skelton J. D. et al.: Complicatins of immunosupession associated with weekly low dose methotrexate. J. Rheumatol. 1991; 18: 1172-1175.

103.Shiroky J. B., Neville C., Esdaile J. M. et al. Low-dose metotrexate with leukovorin (folinic acid) in the managemeht of rheumatoid arthritis: results of a multicentrer random-ized, double-blind, placebo control trial. Arthritis Rheum., 1993; 36: 795-803.

104.Singh R. R., Malaviya A. N., Pandey J. N., Guleiria J. S. Fatal interaction between metotrexate and naproxen (letter). Lancet 1986; i: 1390.

105.Songsiridej N., Furst D. E.: Methotrexate — The rapidly acting drug. Clin. Rheumatol, 1990; 4: 575594.

106.Sperling R. I., Benincaso A. I., Anderson R. J., et al.: Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum. 1992; 35: 376-384.

107.Stewart C. F., Fleming R. A., German B. F., et al.: Aspirin alters metotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum., 1991; 34: 1514-1520.

108.Thomas R., Carrol G. J.: Reduction of leukocyte and interleukin-I beta concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 1993; 36: 12441252.

109.Thomas M. H., Gutterman L. A.: Methotrexate toxicity in patient receiving trimethoprimsulphamethoxazole. J. Rheumatol. 1986: 13: 440-441.

110.Thompson P. M., Watts C., Edelman J., et al.: A controlled two-centre trial of parental methotrexate therapy for refractory rheumatoid arthritis. J. Rheumatol. 1984; II: 760-763.

111.Tishler M., Caspi D., Fishel B., Yaron M.: The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis. 1988; 31: 906-908.

112.Walz Le Blanc B. A. E., Dagenais P., Urowitz M. B., Gladman D. D.: Methotrexate in systemic lupus erythematosus. J. Rheumatol. 1994; 21: 836-838.

113.Weinblatt M. E., Polisson R., Blotner S. D., et al.: The effect of drug therapy on radiographic progression of rheumatoid arthritis. Arthritis Rheum., 1993; 36: 613-619.

114.Weinblatt M. E., Kaplan H., Germain B. F., et al.: Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum. 1994; 37: 1492-1498.

115.Whitaker, J. N., Pinals M. S.: Dermatomyositis/polymyositis. Current therapy in allergy and immunology 1984; Ed. L. M. Lichtenstein, A. S. Fauci. B. C. Decker. Inc. Philadelphia, Toronto, pl 22-125.

116.White-O'Keefe Q. E., Fye K. H., Sack C. D,: Metotrexate and histologic hepatic abnormalities: a meta-analysis. Am. J. Med., 1991; 90: 711-716.

117.White-O'Keefe Q. E., Fye K. H., Sack K. D.: Liver biopsy and methotrexate use: See no evil...? Am. J. Gastroenterol. 1991; 70: 711-716.

118.Wilke W. S., Krall P. L., Scheetz R. J., et al.: Metotrexate for systemic lupus erythematosus: a retrospective analysis of 17 unselected patients. Clin. Exp, Rheumatol., 1991; 9: 581-587.

119.Williams H. J., Willkens R. F., Samuelson C. O., et al.: Comparison of low-dose oral pulse metotrexate and placebo in the treatment of rheumatoid arthritis: a controled trial. Arthritis Rheum., 1985; 28: 721-730.

120.Williams H., Ward J. R., Reading J. C., et al.: Comparison of auranofin, metotrexate, and the combination of both in the treatment of rheumatoid arthritis. Arthritis Rheum., 1992; 35: 259-269.

121.Wilkens R. F., Leonard P. A., Clegg D. D. et al.: Liver histology in patients receving low dose pulse methotrexate for the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 1990; 49: 591-593.

122.Willkens R. F., Urowitz M. B., Stablein D. M., et al.: Comparison of azathioprine, metotrexate, and the combination of both in the treatment of rheumatoid arthritis. Arthritis Rheum. 1992; 35: 849-856.

123.Wise C. M., Vuyyru S., Roberts W. N.: Methotrexate in systemic lupus and lupus-like illness- a

review of 31 patients. Arthritis Rheum. 1994; 37 (suppl.): S-1467.

Wolff R., Asako H., Granger D. N.: Adenosine mediated mithotrexate-induced attenuation of leukocyte adherence and emigration in postcappillary venules. Arthritis Rheum., 1992; 35: S-35.